Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

About this update from Agios Pharmaceuticals, Inc.

CAMBRIDGE, Mass. , Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026 , at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website ( www.agios.com ) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event. About Agios: Fueled by Connections to Transform Rare Diseases™ At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts . To learn more, visit www.agios.com and follow us on LinkedIn and X . Contacts: Investor Contact Morgan Sanford , Vice President, Investor Relations Agios Pharmaceuticals [email protected] Media Contact Eamonn Nolan , Senior Director, Corporate Communications Agios Pharmaceuticals [email protected] Source: Agios Pharmaceuticals, Inc.

View stock analysis, news, and events for Agios Pharmaceuticals, Inc.